@entity3427 in adolescent @entity1 commonly starts as an esthetic problem in young @entity1 and is later complicated by the development of @entity249 and @entity3610 , which are frequent consequences of prolonged @entity3428 . To ascertain whether particular prepubertal clinical manifestations may predict the development of adolescent @entity3427 , we followed 70 @entity1 with @entity9669 ( @entity9669 ) with or without prepubertal @entity12737 (PH) until 3 years (mean age 14.8 +/- 0.9 years) after menarche. Similar follow-up was carried out in six @entity1 with @entity12554 (NC-CAH), treated with @entity701 . In addition, a retrospective study on the incidence of @entity9669 was performed in 139 hirsute teenagers (mean age 17 +/- 1.8 years). @entity251 , @entity2671 , @entity2990 , @entity4418 (basal and after ACTH), luteinizing hormone and follicle-stimulating hormone were evaluated by radioimmunoassay or immunoradio metric assay in the early follicular phase, in cycling subjects. Pelvic ultrasonography was also performed. In the 139 hirsute teenagers, 29 had a history of @entity9669 (21% vs. 0.6% in the general Italian population). Of these 139 @entity1 , NC-CAH was diagnosed in 8 (6%), 5 of whom (63%) had @entity9669 . Of the 70 @entity1 with @entity9669 , @entity3427 was present in 44 (63%). PH was present in 37 of 44 @entity1 (84%) with @entity3427 , but only in 9 of 26 (35%) without @entity3427 . Our results showed that 1) @entity9669 represents a risk factor for the development of postpubertal @entity3427 ; 2) the association with PH seems to increase the risk probability; and 3) @entity1 with @entity3427 due to NC-CAH have a higher incidence of @entity9669 compared with other hirsute @entity1 , but glucocorticoid treatment in such @entity1 prevents the development of @entity3427 . Whether early treatment in the other @entity9669 @entity1 may prevent the development of @entity3427 remains to be established.

XXXX in the adolescent female.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'girls'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome'] @entity9669 :: ('MESH:C567552', 'Disease') :: ['precocious pubarche', 'PP'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['Testosterone'] @entity2990 :: ('CHEBI:16814', 'Chemical') :: ['dehydroepiandrosterone sulphate'] @entity3428 :: ('MESH:D017588', 'Disease') :: ['hyperandrogenism'] @entity12737 :: ('MESH:D006983', 'Disease') :: ['hypertrichosis'] @entity12554 :: ('MESH:C535979', 'Disease') :: ['PP secondary to 21 hydroxylase deficiency'] @entity4418 :: ('MESH:D019326', 'Chemical') :: ['17 alpha-hydroxyprogesterone'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['hydrocortisone'] @entity2671 :: ('MESH:D000735', 'Chemical') :: ['androstenedione'] @entity3427 :: ('MESH:D006628', 'Disease') :: ['hirsutism', 'Hirsutism']
@entity3428 :: (MESH:D017588,Disease) :: ['Hyperandrogenism']
